SUFFERN, N.Y.--(BUSINESS WIRE)--Ryogen LLC, an R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded two new patents this month, bringing the total number of its issued U.S. Patents to 32. U.S. Patent No. 8,765,928 entitled “Identification of isolated genomic nucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4) and variants thereof” was issued on July 1, 2014. The TSSC4 gene is one of several tumor-suppressing fragments on chromosome 11, alterations to which have been associated with some cancers. Ryogen’s portfolio includes U.S. Patent No. 8,722,865 directed to TSSC4. This new patent claims a further method of identifying variants in corresponding DNA or RNA polynucleotides.
Help employers find you! Check out all the jobs and post your resume.
